Hodgkin's lymphoma in adults

[1]  H. Eich,et al.  Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Crump,et al.  How I treat relapsed and refractory Hodgkin lymphoma. , 2011, Blood.

[3]  A. Howell,et al.  The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage , 2009, British Journal of Cancer.

[4]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Wotherspoon,et al.  The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management , 2012, Leukemia & lymphoma.

[7]  V. Diehl,et al.  No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. Fisher,et al.  Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Sydes,et al.  Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Santoro,et al.  Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. , 1985, European journal of cancer & clinical oncology.

[11]  A. Levis,et al.  Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. , 2008, Blood.

[12]  Ralf Küppers,et al.  The biology of Hodgkin's lymphoma , 2009, Nature Reviews Cancer.

[13]  J. Garcia-conde,et al.  Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes , 2007, British journal of haematology.

[14]  L. F. Pracchia,et al.  Hodgkin lymphoma among patients infected with HIV in post-HAART era. , 2007, Clinical lymphoma & myeloma.

[15]  M. Gail,et al.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. , 2005, Journal of the National Cancer Institute.

[16]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[17]  V. Diehl,et al.  Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. , 1998, Blood.

[18]  P. Marynen,et al.  The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. , 2007, Haematologica.

[19]  R. McNally,et al.  Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. , 2012, Blood.

[20]  A. Rossi,et al.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.

[21]  P. Ellis,et al.  COMBINING PROTEIN INTERACTION AND GENE PROFILING METHODS FOR PREDICTING LAPATINIB RESPONSE , 2011 .

[22]  A. Zelenetz,et al.  High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging , 2010, British journal of haematology.

[23]  J. S. Júnior,et al.  18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma , 2010, The Journal of Nuclear Medicine.

[24]  A. Horwich,et al.  Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Raemaekers,et al.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.

[26]  T. Kwee,et al.  Whole‐body MRI for staging Hodgkin lymphoma in a pregnant patient , 2010, American journal of hematology.

[27]  F. Angrilli,et al.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Macintyre,et al.  The value of staging bone marrow trephine biopsy in Hodgkin's Disease , 1987, European journal of haematology.

[29]  V. Diehl,et al.  Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Barrington,et al.  Is marrow biopsy staging for hd and dlbcl obsolete in the pet-ct era , 2011 .

[31]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[32]  N. Le Stang,et al.  Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Nagler,et al.  Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[35]  C. Sebban,et al.  Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial. , 2005 .

[36]  R. Gascoyne,et al.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Rossi,et al.  Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.

[38]  H. Eich,et al.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Cheson,et al.  Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 , 2007, Leukemia & lymphoma.

[40]  C. Carlo-Stella,et al.  Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience , 2010, Leukemia & lymphoma.

[41]  R. Jarrett,et al.  The molecular pathogenesis of Hodgkin lymphoma , 2011, Histopathology.

[42]  A. Levis,et al.  Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi , 2007, Annals of Hematology.

[43]  R. Greil,et al.  Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Salles,et al.  Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Gascoyne,et al.  High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. , 2005, Blood.

[46]  S. Fanti,et al.  Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. , 2011, Clinical lymphoma, myeloma & leukemia.

[47]  J. Raemaekers,et al.  Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.

[48]  M. Federico,et al.  High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  V. Diehl,et al.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Scott E. Smith,et al.  Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma , 2010 .

[52]  K. Maclennan,et al.  Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[54]  H. Amthauer,et al.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.

[55]  S. Pileri,et al.  Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. , 2007, Haematologica.

[56]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[57]  R. Tsang,et al.  Hodgkin’s lymphoma , 2018, Concise Notes in Oncology for MRCP and MRCS.

[58]  P. Borchmann,et al.  Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. , 2011, Blood.

[59]  V. Diehl,et al.  Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). , 2008, Blood.

[60]  E. Cardonick,et al.  Use of chemotherapy during human pregnancy. , 2004, The Lancet. Oncology.

[61]  V. Diehl,et al.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Feugier,et al.  High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results , 2009, Haematologica.

[63]  B. Coiffier,et al.  Nodular, lymphocyte‐predominant Hodgkin lymphoma , 2010, Cancer.

[64]  R. Gascoyne,et al.  Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  R. Greil,et al.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Bingshu E. Chen,et al.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. , 2012, The New England journal of medicine.

[67]  Y. Oki,et al.  Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma , 2008, Cancer.

[68]  E. Noordijk,et al.  First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) , 2005 .

[69]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[70]  P. Gobbi,et al.  Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[72]  Ronald C. Chen,et al.  Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[74]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  V. Diehl,et al.  Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. , 2000, Blood.

[76]  V. Diehl,et al.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). , 2008, Blood.

[77]  T. Nihashi,et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Pettitt,et al.  Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  R. Houot,et al.  for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) , 2013 .

[80]  N. Skoetz,et al.  Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma , 2007, The Cochrane database of systematic reviews.

[81]  A. Zelenetz,et al.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.

[82]  H. Johnsen,et al.  Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs , 2012, Haematologica.

[83]  V. Diehl,et al.  Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. d'Amore,et al.  Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. , 2006, Haematologica.

[85]  R. Tsang,et al.  Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. , 2010, Seminars in radiation oncology.

[86]  V. Diehl,et al.  Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  E. Noordijk,et al.  Survival after Hodgkin lymphoma , 2009, Cancer.

[88]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[89]  G. Bonadonna,et al.  ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  L. Kalish,et al.  Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis , 1993, Cancer.

[91]  R Peto,et al.  Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Franklin,et al.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. , 2005, The Cochrane database of systematic reviews.

[93]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[94]  P. Hall,et al.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  T. Habermann,et al.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma , 2010, American journal of hematology.

[96]  N. Skoetz,et al.  Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. , 2011, The Cochrane database of systematic reviews.

[97]  G. Canellos,et al.  Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy? , 2011, Current hematologic malignancy reports.

[98]  A. Levis,et al.  VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  C. Poirot,et al.  Management of fertility in patients treated for Hodgkin’s lymphoma , 2011, Haematologica.

[100]  V. Diehl,et al.  New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Connors,et al.  Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  C. Flowers,et al.  Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States , 2010, Advances in hematology.

[104]  A. López-Guillermo,et al.  Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. , 2007, Haematologica.

[105]  R. Foà,et al.  Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkinlymphoma , 2009, Leukemia & lymphoma.

[106]  L. Robison,et al.  High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  H. Hjalgrim,et al.  Incidence of Hodgkin's disease in Nordic countries , 2001, The Lancet.

[108]  S. Baxi,et al.  State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship , 2010, Current oncology reports.

[109]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[110]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[111]  G. Koren,et al.  The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy , 2007, Haematologica.

[112]  D. Hasenclever,et al.  Resection alone in 58 children with limited stage, lymphocyte‐predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphoma , 2007, Cancer.

[113]  J. Radford,et al.  The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre , 2002, British journal of haematology.

[114]  Jeffrey W. Scott,et al.  Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma , 2009, British journal of haematology.

[115]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[116]  R. Naumann,et al.  Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma , 2010, British journal of haematology.

[117]  J. Raemaekers,et al.  Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. , 2007, International journal of radiation oncology, biology, physics.

[118]  R. Prescott,et al.  A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). , 2002, European journal of cancer.

[119]  Olker,et al.  A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .

[120]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  A. Levis,et al.  A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. , 2004, Clinical lymphoma.

[123]  Anthony J. Swerdlow,et al.  Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.